An observational study comparing ormeloxifene with evening primrose oil for benign breast diseases

Authors

DOI:

https://doi.org/10.3126/ajms.v14i7.51995

Keywords:

Fibroadenosis; Fibrocystic breast disease; Mastodynia

Abstract

Background: Fibroadenosis, popularly termed aberrations of normal development and involution (ANDI), is by far the most common female breast presentation to a surgeon. ANDI accounts for the most common breast lumps in women <30 years of age. Mastalgia, a significant spectrum of ANDI, is usually classified as (1) cyclical mastalgia (more common) and (2) non-cyclical mastalgia. Breast nodularity, the other spectrum of ANDI may either present as a predominant feature or coexist with mastalgia.

Aims and Objectives: The aims of this study were to comparatively study ormeloxifene and evening primrose oil with respect to regression of fibroadenosis and mastalgia and evaluate their side effects.

Materials and Methods: This prospective study was conducted in the Department of General Surgery of Calcutta National Medical College and Hospital, Kolkata from February 15th, 2021 to February 14th, 2022, after obtaining prior Institutional Ethical Committee Clearance. Two hundred and eighty patients were equally divided into two groups of 140 in each and screened for inclusion in this study.

Results: At the start of treatment, Group A (Ormeloxifene) presented with a mean visual analog scale (VAS) score value of 5.71, while patients of Group B presented with a similar mean VAS score value of 5. Group B recorded a VAS score of 4.50 at the end of the 6th month, while Group A recorded a significant downhill slope of negligible mean VAS score value of 0.80 at the of the 6th month. In breast nodularity gradings too, Group A showed significant down staging of grades returning, 95% confidence interval at the end of 6th month as 1.144, while 2.280 was recorded for Group B.

Conclusion: Benign breast disease is a common presenting problem in females of reproductive age. Ormeloxifene can be a better alternative to evening primrose oil in both cyclical and non-cyclical types of mastalgia. Larger trials are however required, to finally conclude on.

Downloads

Download data is not yet available.
Abstract
29
PDF
77

Downloads

Published

2023-07-01

How to Cite

Anupam Banerjee, Dipan Mukhopadhyay, Tapati Mondal, & Swarup Chakraborty. (2023). An observational study comparing ormeloxifene with evening primrose oil for benign breast diseases. Asian Journal of Medical Sciences, 14(7), 117–121. https://doi.org/10.3126/ajms.v14i7.51995

Issue

Vol. 14 No. 7 (2023)

Section

Original Articles

License

Copyright (c) 2023 Asian Journal of Medical Sciences

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Authors who publish with this journal agree to the following terms:

  1. The journal holds copyright and publishes the work under a Creative Commons CC-BY-NC license that permits use, distribution and reprduction in any medium, provided the original work is properly cited and is not used for commercial purposes. The journal should be recognised as the original publisher of this work.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).